Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

作者：Hartmut Döhner, Courtney Denton Dinardo, Frederick R. Appelbaum, Charles Craddock, Hervé Dombret, Benjamin L. Ebert, Pierre Fenaux, Lucy A. Godley, Robert Paul Hasserjian, Richard A. Larson, Ross L. Levine, Yasushi Miyazaki, Dietger W. Niederwieser, Gert Jan Ossenkoppele, Christoph Röllig, Jorge Sierra, Eytan M. Stein, Martin S. Tallman, Hwei‐Fang Tien, Jianxiang Wang, Agnieszka Wierzbowska, Andrew H. Wei, Bob Löwenberg · 发表于：Blood · 年份：2024 · DOI：10.1182/blood.2024025409 · 被引用次数：242 · 研究领域：Acute Myeloid Leukemia Research、Chronic Myeloid Leukemia Treatments、Acute Lymphoblastic Leukemia research

ABSTRACT: The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.